NEW YORK (GenomeWeb News) — Vermillion, formerly known as Ciphergen Biosystems, today said it plans to gross around $20.5 million in a private stock placement to a group of existing and new investors.
 
Vermillion said it plans to use the net proceeds from the transaction for general working capital needs.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.